Spruce Biosciences, Inc. (SPRB)
NASDAQ: SPRB · Real-Time Price · USD
0.400
+0.018 (4.68%)
At close: Dec 20, 2024, 4:00 PM
0.399
-0.001 (-0.15%)
After-hours: Dec 20, 2024, 5:59 PM EST

Company Description

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders.

The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.

It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial.

Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan.

The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Spruce Biosciences, Inc.
Spruce Biosciences logo
Country United States
Founded 2014
IPO Date Oct 9, 2020
Industry Biotechnology
Sector Healthcare
Employees 29
CEO Javier Szwarcberg

Contact Details

Address:
611 Gateway Boulevard, Suite 740
South San Francisco, California 94080
United States
Phone 415 655 4168
Website sprucebiosciences.com

Stock Details

Ticker Symbol SPRB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $15.00
CIK Code 0001683553
CUSIP Number 85209E109
ISIN Number US85209E1091
Employer ID 81-2154263
SIC Code 2834

Key Executives

Name Position
Dr. Javier Szwarcberg M.D., M.P.H. Chief Executive Officer and Director
Michael G. Grey Executive Chairman
Samir M. Gharib CPA, M.B.A. President and Chief Financial Officer
Dr. Ralph William Charlton III, M.D. Chief Medical Officer
P. J. Ramtin Senior Vice President of Business Operations
Heidi Petersen M.P.H. Senior Vice President of Regulatory and Quality

Latest SEC Filings

Date Type Title
Dec 10, 2024 8-K Current Report
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 10-Q Quarterly Report
Nov 12, 2024 8-K Current Report
Oct 28, 2024 8-K Current Report
Oct 23, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Aug 12, 2024 10-Q Quarterly Report
Aug 12, 2024 8-K Current Report